Post-earnings recap
Reported
Thu, Jul 28, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Cytokinetics reported a loss per share of $0.29, which was slightly below expectations. The stock fell by nearly 4% in response to the lack of revenue data and guidance. Investors may be concerned about the company's future performance without clear direction from management.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.29 | N/A | -5.45% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding the current financial outlook. They emphasized the importance of their clinical programs.
Management did not provide specific guidance for future performance.
The company is focusing on its ongoing clinical trials.